Tag: view

Ajay Srivastava of Dimensions Corporate says \”we are in that zone where people are comfortable where they are and therefore willing to carry the investment and also make more investment. So, yes, there are fundamental factors, but to me the most important is human psychology. We are feeling good today and when we feel good, we want to do things and become more expensive.\”

Foram Parekh shares insights on CDMO companies\’ positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus\’s earnings improvement, Sun Pharma\’s specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy\’s.

Sudeep Shah, from SBI Securities, predicts market consolidation and bullish movement towards 22,950-23,000. He further Recommends Aditya Birla Capital and MCX stocks and anticipates positive trends in the pharma sector, specifically mentioning Concord Bio.

Market expert Joshi praises TCS\’s outstanding financial performance, expecting a stock re-rating. Anticipates positive sector impact and growth in BFSI, energy, manufacturing, life sciences, and healthcare industries based on TCS\’s stellar results.

Mirae Asset Investment Managers are bullish on India\’s economy, emphasizing growth prospects. Ankit Jain sees opportunities in midcap companies, consumer, and financial services sectors. Positive outlook despite stretched valuations, with focus on earnings growth and investment opportunities in various sectors. Jain says: \”The 1-year forward P/E ratio for Nifty stands at 22.5x, while for the Midcap 100, it is 24.5x, representing a premium of 12-15% over their respective 10-year averages.\”

Deven Choksey emphasizes individual stock investments over market view, focusing on sectors like IT, specialty chemicals, and pharma. He remains cautious on market exuberance and suggests strategic investments during corrections for long-term gains. Choksey says: \”The market is scaling up too quickly and too early, maybe that is where one is not fully comfortable.\”